MoyerVA. Risk Assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med, 2013 [Epub ahead of print]; DOI: 10.7326/M13-2747.
2.
BellcrossCA, LemkeAA, PapeLS, TessAL, MeisnerLT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med, 2009; 11:783–789.
3.
Georgia Breast Cancer Genomics Consortium. Referral screening tool (RST). Available at: www.breastcancergenescreen.org Accessed January22, 2014.
4.
MoyerVA. Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med, 2013 [Epub ahead of print]; DOI:10.7326/0003-4819-159-10-201311190-00718.
5.
VisvanathanK, HurleyP, BantugE, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol., 2013; 31:2942–2962.
6.
National Institutes o Health, National Cancer Institute. Breast cancer risk assessment tool. www.cancer.gov/bcrisktool Accessed January10, 2014.
7.
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine. IBIS breast cancer risk evaluation tool. Available at: www.ems-trials.org/riskevaluator Accessed January10, 2014.
8.
GailMH, BrintonLA, ByarDP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst, 1989; 81:1879–1886.
9.
CostantinoJP, GailMH, PeeD, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst, 1999; 91:1541–1548.
10.
SaslowD, BoetesC, BurkeW, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin, 2007; 57:75–89.
11.
VogelVG, CostantinoJP, WickerhamDL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006; 295:2727–2741.
12.
VogelVG, CostantinoJP, WickerhamDL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila), 2010; 3:696–706.
13.
GossPE, IngleJN, Ales-MartinezJE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med, 2011; 364:2381–2391.
14.
CheungAM, TileL, CardewS, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: A nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol, 2012; 13:275–284.
15.
CuzickJ, SestakI, ForbesJF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 2013 [Epub ahead of print]; DOI: 10.1016/S0140-6736(13)62292-8.
16.
FilesJA, StanDL, AllenSV, PruthiS. Chemoprevention of breast cancer. Womens Health (Lond Engl), 2012; 8:635–646.
17.
Mac BrideMB, PruthiS, BeversT. The evolution of breast self-examination to breast awareness. Breast J, 2012; 18:641–643.
